| FORMYCON AG |
| Deutschland |
| Gesundheit |
| DE000A1EWVY8 / A1EWVY |
| FYB (Frankfurt) |
| FRA:FYB, ETR:FYB, FYB:GR |
| - |
| https://www.formycon.com/ |
|
Formycon AG is a leading independent biotechnology company headquartered in Planegg, Germany, specializing in the development of high-quality biosimilars, which are cost-effective follow-on versions of complex biopharmaceutical medicines. The company..
>Volltext.. |
| 334.13 Mio. EUR |
| 290.81 Mio. EUR |
| 62.67 Mio. EUR |
| 10.44 Mio. EUR |
| -25.72 Mio. EUR |
| -1.46 EUR |
| 8.71 Mio. EUR |
| 52.99 Mio. EUR |
| -5 Mio. EUR |
| 0.96 |
| 18.28% |
| 85.2% |
| - |
| - |
| - |
| - |
| FORMYCON, NANOHALE |
| 02.11.26 |
|
||||
|
||||
|
||||
|